Loading
Pulmonx Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Florin Daniel P, was filed 05 Jun 2025.
Pulmonx Corp: what insiders have been doing
This page follows insider dealings at Pulmonx Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (23 October 2025 to 23 October 2026), 48 filings came from 8 insiders.
Only sales appear on the open market, 40 sales in all totalling €346k, filed by 5 insiders. Biggest ticket of the year: €74k, sold by French Glendon E. III and made public on 3 September 2026 (0.099% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 48 filings here. Over the whole record (from 2020), the tally stands at 11 purchases and 291 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 90.5 m USD and net income at -54.0 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
401
Thresholds
n/a
Buy Volume
€2M
11 ops. · all time
Sell Volume
€169M
291 ops. · all time
Who traded when
BuySaleDavid Aaron Lehman30 sales
Geoffrey Beran Rose29 sales
Glendon E. French III13 sales
Srikanth Radhakrishnan8 sales
Mehul Joshi5 sales
Steven S. Williamson5 sales
+2 other insiders
Since the insiders bought
- -53.0%Entry US$3.17 · Close at T+365 US$1.49
- -77.8%Entry US$7.51 · Close at T+365 US$1.67
- +73.7%Entry US$6.51 · Close at T+365 US$11.31
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,509 of 26,248 companies
17.8
score / 100
Value4
Quality32
FCF yld-43%
Earn yld-70%
EV/EBITDA·
ROE-89%
Gross mgn74%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.82
Analyst consensus
5 analysts1.80/5
US$2.50Target US$3.40(+87%)US$5.00
Income statement
RevenueUS$90.5M
Gross profitUS$67.1M74% margin
EBITDA-US$49.2M-54% margin
Net income-US$54M-55.0% margin
Valuation
PER (forward)-1.9x
P/Book2.0x
Beta0.34
Balance sheet & cash
Market capUS$76.9M
Total debtUS$56.4M
Free Cash Flow-US$32.8M
Debt / Equity143%
Profitability & ownership
ROE-88.9%
ROA-22.1%
% insiders4.6%
% institutions62.8%
Last declaration on 3 September 2026
Declarations401 total
2,213 shares@ US$2.260.0058% mcap0.2% of flowCommon StockSEC:0001804146-26-000004:0
2,390 shares@ US$2.260.0063% mcap0.2% of flowCommon StockSEC:0001804146-26-000004:1
1,530 shares@ US$2.260.0040% mcap0.1% of flowCommon StockSEC:0001804146-26-000004:2
1,746 shares@ US$2.260.0046% mcap0.2% of flowCommon StockSEC:0001804146-26-000004:3
2,643 shares@ US$2.260.0069% mcap18.0% of flowCommon StockSEC:0002098678-26-000004:0
2,121 shares@ US$2.260.0056% mcap14.4% of flowCommon StockSEC:0002098678-26-000004:1
5,863 shares@ US$2.260.015% mcap39.8% of flowCommon StockSEC:0002098678-26-000004:3
3,618 shares@ US$2.260.0095% mcap24.6% of flowCommon StockSEC:0002098678-26-000004:2
3,807 shares@ US$2.260.0100% mcap6.4% of flowCommon StockSEC:0001354228-26-000005:0
2,224 shares@ US$2.260.0058% mcap3.7% of flowCommon StockSEC:0001354228-26-000005:1
3,476 shares@ US$2.260.0091% mcap5.8% of flowCommon StockSEC:0001354228-26-000005:2
4,827 shares@ US$2.260.013% mcap8.1% of flowCommon StockSEC:0001354228-26-000005:3
4,098 shares@ US$2.260.011% mcap0.1% of flowCommon StockSEC:0001805624-26-000004:0
37,784 shares@ US$2.260.099% mcap1.1% of flowCommon StockSEC:0001805624-26-000004:1
40,000 shares0Common StockSEC:0001644557-26-000022:0
40,000 shares0Common StockSEC:0001034413-26-000002:0
40,000 shares0Common StockSEC:0001402459-26-000002:0
100,000 shares0Common StockSEC:0001804146-26-000001:4
175,000 shares0Common StockSEC:0002098678-26-000001:4
150,000 shares0Common StockSEC:0001354228-26-000002:4
6,737 shares@ US$1.430.1% of flowCommon StockSEC:0001805624-26-000001:1
58,368 shares@ US$1.430.7% of flowCommon StockSEC:0001805624-26-000001:2
2,125 shares@ US$1.430.1% of flowCommon StockSEC:0001804146-26-000001:1
1,861 shares@ US$1.430.1% of flowCommon StockSEC:0001804146-26-000001:2
2,911 shares@ US$1.430.1% of flowCommon StockSEC:0001804146-26-000001:3
25 of 401 declarations
About Pulmonx Corp
Pulmonx Corp. (ticker: LUNG) is a U.S.-based medical technology company listed on the Nasdaq market in the United States. For French, Belgian, and Swiss investors, it is best viewed as a specialized respiratory-care business focused on minimally invasive treatment of severe emphysema, a debilitating form of COPD. The company was founded in 1995 and has built its franchise around interventional pulmonology, combining therapeutic devices, patient-selection tools, and diagnostic/planning software to support physicians across the treatment pathway. ([stockanalysis.com](https://stockanalysis.com/stocks/lung/company/?utm_source=openai))
The commercial core of Pulmonx is the Zephyr Endobronchial Valve, an implantable bronchial valve designed for selected patients with severe emphysema who remain highly symptomatic despite medical management or who are not suitable for surgical options. The company also markets the Chartis Pulmonary Assessment System, which helps clinicians evaluate airflow and identify appropriate target areas, and the LungTraX platform, a cloud-based quantitative CT analysis service that supports patient identification and procedural planning. This makes Pulmonx more than a single-device company: it is a treatment-enablement platform built around patient screening, physician training, and clinical workflow integration. ([investors.pulmonx.com](https://investors.pulmonx.com/investor-faqs?utm_source=openai))
Read moreShow less
From a competitive standpoint, Pulmonx occupies a niche leadership position in interventional pulmonology. Its public materials describe the company as a global leader in minimally invasive treatments for lung disease, with commercial availability across the United States, Europe, Australia, Asia, Latin America, and other markets. The corporate headquarters is in Redwood City, California, and the group also maintains a presence in Neuchâtel, Switzerland. That geographic footprint matters because Pulmonx operates in a highly regulated, reimbursement-sensitive market where commercial adoption depends on physician education, procedural infrastructure, and local market access. ([craft.co](https://craft.co/pulmonx/locations?utm_source=openai))
Recent developments have centered on operating execution and financial reporting. Pulmonx released full-year 2025 results and first-quarter 2026 results, with management describing the period as one of transition and emphasizing actions to refocus the U.S. sales organization and advance clinical programs. The company has also highlighted ongoing global adoption of Zephyr Valve procedures. For investors, this creates a classic med-tech profile: differentiated technology with meaningful long-term clinical opportunity, but also dependence on procedure growth, reimbursement dynamics, regulatory execution, and commercialization discipline. On the Nasdaq in the United States, Pulmonx remains a specialized healthcare name with a clear niche, an international footprint, and a risk/reward profile tied to adoption of its lung-volume-reduction platform. ([investors.pulmonx.com](https://investors.pulmonx.com/news-releases/news-release-details/pulmonx-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
